Clinical Trial Update: A Trial of SHR-1210 in Combination With Apatinib in Patients With Unresectable HCC [Phase 2]

View source ↗

Summary

Phase 2 trial exploring SHR-1210 with apatinib in unresectable hepatocellular carcinoma (HCC).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Apatinib (apatinib)
• SHR-1210 (camrelizumab)

Snippet

Sponsor: Yanqiao Zhang | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: UNKNOWN